Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial

Choy, Ernest; Isenberg, David; Garrood, Toby; Farrow, Stuart; Ioannou, Yiannis; A. Bird, H.; T. CHEUNG, N.; Williams, Buddug; L. Hazleman, B.; Price, R.; Yoshizaki, Kazuyuki; Nishimoto, Naoki; Kishimoto, Tadamitsu; S. Panayi, G.

doi:10.1002/art.10623

Public

Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double‐blind, placebo‐controlled, dose‐escalation trial

Published in Arthritis & Rheumatism • Dec 1, 2002

Authors:

Ernest Choy

David Isenberg

Toby Garrood

Abstract

OBJECTIVE: To investigate the safety and efficacy of MRA, a recombinant human anti-interleukin-6 (anti-IL-6) receptor monoclonal antibody of the IgG1 subclass that inhibits the function of IL-6, in patients with established rheumatoid arthritis (RA). METHODS: A randomized, double-blind, placebo-cont...

Subject

Medicine

Placebo

Rheumatoid arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!